Dr Cook on Real-World Data With Bridging Therapy and Axi-Cel in Relapsed/Refractory LBCL
Michael R. Cook, MD, discusses real-world data associated with the utilization of bridging therapy prior to treatment with axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma.
Michael R. Cook, MD, assistant professor of clinical medicine, Hematology-Oncology, Abramson Cancer Center Penn Presbyterian, Penn Medicine, discusses real-world real-world data associated with the utilization of bridging therapy prior to treatment with axicabtagene ciloleucel (axi-cel; Yescarta) in patients with relapsed/refractory large B-cell lymphoma (LBCL).
Related Videos
Related Content
